{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02300701",
      "orgStudyIdInfo": {
        "id": "ADAPT"
      },
      "organization": {
        "fullName": "Guy's and St Thomas' NHS Foundation Trust",
        "class": "OTHER"
      },
      "briefTitle": "Role of Anti-IgE in Severe Childhood Eczema",
      "officialTitle": "The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema",
      "acronym": "ADAPT"
    },
    "statusModule": {
      "statusVerifiedDate": "2019-08",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2014-12"
      },
      "primaryCompletionDateStruct": {
        "date": "2018-08",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2018-08",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2014-11-21",
      "studyFirstSubmitQcDate": "2014-11-24",
      "studyFirstPostDateStruct": {
        "date": "2014-11-25",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2019-08-08",
      "lastUpdatePostDateStruct": {
        "date": "2019-08-09",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Guy's and St Thomas' NHS Foundation Trust",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "King's College London",
          "class": "OTHER"
        },
        {
          "name": "National Institute for Health Research, United Kingdom",
          "class": "OTHER_GOV"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": true
    },
    "descriptionModule": {
      "briefSummary": "To evaluate the efficacy of anti-IgE (Omalizumab/Xolair) in children with severe eczema.",
      "detailedDescription": "To address the value of anti-IgE in children with severe eczema."
    },
    "conditionsModule": {
      "conditions": [
        "Atopic Eczema",
        "Atopic Dermatitis",
        "Child"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 62,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Xolair/Omalizumab",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: Xolair"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Drug: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Xolair",
          "description": "According to manufacturer's instructions",
          "armGroupLabels": [
            "Xolair/Omalizumab"
          ],
          "otherNames": [
            "Omalizumab"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "Placebo",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Improvement in atopic eczema",
          "timeFrame": "24 weeks after treatment commences"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Children between the ages of 4-19 years\n2. Severe eczema\n3. Raised SpIgE or SPT to at least 1 food allergen or 1 aeroallergen AND/OR\n4. Clinical impression that allergic exposures cause worsening eczema.\n5. Total IgE level \\>300 kU/l\n6. Clinically proven IgE-mediated allergic disease.\n7. Written informed consent to participate.\n\nExclusion criteria:\n\n1. Inability to comply with 2-4 weekly injections and clinic visits\n2. Evidence of underlying immune compromise, autoimmune disease, immune complex mediated conditions.\n3. Uncontrolled infection or unstable eczema.\n4. Malignancy or a history of malignancy.\n5. Pre-existing hepatic or renal impairment\n6. Known cardiovascular or ischaemic cerebrovascular abnormality.\n7. Other serious or uncontrolled systemic disease.\n8. Pregnancy or lactation.\n9. Known history of hypersensitivity or anaphylaxis to anti-IgE injections or its constituents.\n10. Insufficient understanding of the trial assessments.\n11. Participation in a CTIMP in the previous 60 days or (if known) 4 half-lives of the relevant medication, whichever is the greater.\n12. Investigator feels that there is a good clinical reason why the child would be unsuitable.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "4 Years",
      "maximumAge": "19 Years",
      "stdAges": [
        "CHILD",
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "S Chan, MBBS, MD",
          "affiliation": "Guy's and St Thomas' Hospitals NHS Foundation Trust",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Guy's and St Thomas' NHS Foundation Trust",
          "city": "London",
          "zip": "SE1 7EH",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.50853,
            "lon": -0.12574
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "31764962",
          "type": "DERIVED",
          "citation": "Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial. JAMA Pediatr. 2020 Jan 1;174(1):29-37. doi: 10.1001/jamapediatrics.2019.4476."
        },
        {
          "pmid": "28330497",
          "type": "DERIVED",
          "citation": "Chan S, Cornelius V, Chen T, Radulovic S, Wan M, Jahan R, Lack G. Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial. Trials. 2017 Mar 22;18(1):136. doi: 10.1186/s13063-017-1809-7."
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D003876",
          "term": "Dermatitis, Atopic"
        }
      ],
      "ancestors": [
        {
          "id": "D012873",
          "term": "Skin Diseases, Genetic"
        },
        {
          "id": "D030342",
          "term": "Genetic Diseases, Inborn"
        },
        {
          "id": "D009358",
          "term": "Congenital, Hereditary, and Neonatal Diseases and Abnormalities"
        },
        {
          "id": "D003872",
          "term": "Dermatitis"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D017443",
          "term": "Skin Diseases, Eczematous"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000069444",
          "term": "Omalizumab"
        }
      ],
      "ancestors": [
        {
          "id": "D000888",
          "term": "Antibodies, Anti-Idiotypic"
        },
        {
          "id": "D000906",
          "term": "Antibodies"
        },
        {
          "id": "D007136",
          "term": "Immunoglobulins"
        },
        {
          "id": "D007162",
          "term": "Immunoproteins"
        },
        {
          "id": "D001798",
          "term": "Blood Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D061067",
          "term": "Antibodies, Monoclonal, Humanized"
        },
        {
          "id": "D000911",
          "term": "Antibodies, Monoclonal"
        },
        {
          "id": "D012712",
          "term": "Serum Globulins"
        },
        {
          "id": "D005916",
          "term": "Globulins"
        }
      ]
    }
  },
  "hasResults": false
}